Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
JP Morgan raises target price on GSK
(Sharecast News) - Analysts at JP Morgan raised their target price on drugmaker GSK to £22.50 on Monday on improving investor perception. JP Morgan said after GSK's full-year earnings per share came in 2% ahead of consensus and its in-line FY26 constant currency guide, it had opted to trim 26/27E EPS by 1-2%.
The broker noted that GSK has rallied strongly off a low-PE post-results, and said it thinks this was due to continued operational delivery, as well as new chief executive Luke Miels' focus on accelerating R&D, low-risk BD and underwriting GSK's £40bn 31E revenue target and flat margins through dolutegravir LOE 28-31E.
"While we think more pipeline is needed to achieve the sales and margin targets we see momentum in R&D (7 PIII starts 25E, GSK flagging potential new pivotal trial starts 26/27E for its B7-H3 & B7-H4 ADCs, GSK'981 (KITi) for GIST, Cabenuva Q4M, LA TSLP and regimen selection for Q6M HIV to be announced at a June investor event)" said JPM.
"We see the stock as likely to hold these perception-shift gains but prefer not to chase hence raise our TP to £22.50 and maintain 'neutral'."
Reporting by Iain Gilbert at Sharecast.com
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
